Molecular imaging for cancer diagnosis and surgery

Advanced Drug Delivery Reviews

Volumn 66, Issue , 2014, Pages 90-100

  Hussain, Timon ^a   Nguyen, Quyen T ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cancer diagnosis; Fluorescence guided surgery; Molecular imaging

Indexed keywords

CANCER DIAGNOSIS; GUIDED SURGERY; IMAGING MODALITY; MOLECULAR PROBES; PATIENT POPULATION; SCREENING PROGRAMS; SURGICAL RESECTION; THERAPEUTIC AGENTS;

DIAGNOSIS; DISEASES; FLUORESCENCE; MAGNETIC RESONANCE IMAGING; PROBES; SURGERY; TUMORS;

MOLECULAR IMAGING;

AMINOLEVULINIC ACID; FLUORESCENT DYE; FLUORODEOXYGLUCOSE F 18; GADOLINIUM; GADOLINIUM CHELATE; RADIOISOTOPE; SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLE;

BREAST CANCER; CANCER DIAGNOSIS; CANCER STAGING; CANCER SURGERY; CANCER TISSUE; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; ECHOGRAPHY; HUMAN; LYMPH NODE METASTASIS; MELANOMA; MICROBUBBLE; MOLECULAR IMAGING; MOLECULAR PROBE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OVARY CANCER; PET SCANNER; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; SENSITIVITY ANALYSIS; SOLID TUMOR; ULTRASOUND TRANSDUCER;

CANCER DIAGNOSIS; FLUORESCENCE GUIDED SURGERY; MOLECULAR IMAGING;

ANIMALS; HUMANS; MOLECULAR IMAGING; NEOPLASM STAGING; NEOPLASMS;

EID: 84896690165     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2013.09.007     Document Type: Review

References (141)

1. American College of Surgeons National Cancer Database Public Reports 2013 (accessed 05.02.2013). http://www.cromwell.facs.org/BMarks/BMPub/Ver10/bm_reports.cfm.
2. Scott W.J., Howington J., Feigenberg S., Movsas B., Pisters K. Treatment of non-small cell lung cancer stage I and stage II: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 2007, 132:234S-242S.
3. Schiller J.H., Harrington D., Belani C.P., Langer C., Sandler A., Krook J., Zhu J., Johnson D.H. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N. Engl. J. Med. 2002, 346:92-98.
4. Weissleder R., Pittet M.J. Imaging in the era of molecular oncology. Nature 2008, 452:580-589.
5. Kircher M.F., Willmann J.K. Molecular body imaging: MR imaging, CT, and US. Part I. Principles. Radiology 2012, 263:633-643.
6. Vogelstein B., Kinzler K.W. Cancer genes and the pathways they control. Nat. Med. 2004, 10:789-799.
7. Elias D.R., Thorek D.L., Chen A.K., Czupryna J., Tsourkas A. In vivo imaging of cancer biomarkers using activatable molecular probes. Cancer Biomark 2008, 4:287-305.
8. Kircher M.F., Willmann J.K. Molecular body imaging: MR imaging, CT, and US. Part II. Applications. Radiology 2012, 264:349-368.
9. Kircher M.F., Hricak H., Larson S.M. Molecular imaging for personalized cancer care. Mol. Oncol. 2012, 6:182-195.
10. Majumder P.K., Febbo P.G., Bikoff R., Berger R., Xue Q., McMahon L.M., Manola J., Brugarolas J., McDonnell T.J., Golub T.R., Loda M., Lane H.A., Sellers W.R. mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat. Med. 2004, 10:594-601.
11. Juweid M.E., Cheson B.D. Positron-emission tomography and assessment of cancer therapy. N. Engl. J. Med. 2006, 354:496-507.
12. Kostakoglu L., Coleman M., Leonard J.P., Kuji I., Zoe H., Goldsmith S.J. PET predicts prognosis after 1cycle of chemotherapy in aggressive lymphoma and Hodgkin's disease. J. Nucl. Med. 2002, 43:1018-1027.
13. Spaepen K., Stroobants S., Dupont P., Vandenberghe P., Thomas J., de Groot T., Balzarini J., De Wolf-Peeters C., Mortelmans L., Verhoef G. Early restaging positron emission tomography with (18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma. Ann. Oncol. 2002, 13:1356-1363.
14. Hartmann L.C., Keeney G.L., Lingle W.L., Christianson T.J., Varghese B., Hillman D., Oberg A.L., Low P.S. Folate receptor overexpression is associated with poor outcome in breast cancer. Int. J. Cancer 2007, 121:938-942.
15. Hoffman J.M., Gambhir S.S. Molecular imaging: the vision and opportunity for radiology in the future. Radiology 2007, 244:39-47.
16. Ellegala D.B., Leong-Poi H., Carpenter J.E., Klibanov A.L., Kaul S., Shaffrey M.E., Sklenar J., Lindner J.R. Imaging tumor angiogenesis with contrast ultrasound and microbubbles targeted to alpha(v)beta3. Circulation 2003, 108:336-341.
17. Winter P.M., Caruthers S.D., Kassner A., Harris T.D., Chinen L.K., Allen J.S., Lacy E.K., Zhang H., Robertson J.D., Wickline S.A., Lanza G.M. Molecular imaging of angiogenesis in nascent Vx-2 rabbit tumors using a novel alpha(nu)beta3-targeted nanoparticle and 1.5Tesla magnetic resonance imaging. Cancer Res. 2003, 63:5838-5843.
18. Lijowski M., Caruthers S., Hu G., Zhang H., Scott M.J., Williams T., Erpelding T., Schmieder A.H., Kiefer G., Gulyas G., Athey P.S., Gaffney P.J., Wickline S.A., Lanza G.M. High sensitivity: high-resolution SPECT-CT/MR molecular imaging of angiogenesis in the Vx2 model. Invest. Radiol. 2009, 44:15-22.
19. Juuti A., Lundin J., Nordling S., Louhimo J., Haglund C. Epithelial MMP-2 expression correlates with worse prognosis in pancreatic cancer. Oncology 2006, 71:61-68.
20. Talvensaari-Mattila A., Paakko P., Turpeenniemi-Hujanen T. Matrix metalloproteinase-2 (MMP-2) is associated with survival in breast carcinoma. Br. J. Cancer 2003, 89:1270-1275.
21. Hirvonen R., Talvensaari-Mattila A., Paakko P., Turpeenniemi-Hujanen T. Matrix metalloproteinase-2 (MMP-2) in T(1-2)N0 breast carcinoma. Breast Cancer Res. Treat. 2003, 77:85-91.
22. Giannelli G., Bergamini C., Marinosci F., Fransvea E., Quaranta M., Lupo L., Schiraldi O., Antonaci S. Clinical role of MMP-2/TIMP-2 imbalance in hepatocellular carcinoma. Int. J. Cancer 2002, 97:425-431.
23. Ellenrieder V., Alber B., Lacher U., Hendler S.F., Menke A., Boeck W., Wagner M., Wilda M., Friess H., Buchler M., Adler G., Gress T.M. Role of MT-MMPs and MMP-2 in pancreatic cancer progression. Int. J. Cancer 2000, 85:14-20.
24. Sier C.F., Kubben F.J., Ganesh S., Heerding M.M., Griffioen G., Hanemaaijer R., van Krieken J.H., Lamers C.B., Verspaget H.W. Tissue levels of matrix metalloproteinases MMP-2 and MMP-9 are related to the overall survival of patients with gastric carcinoma. Br. J. Cancer 1996, 74:413-417.
25. Querol M., Bogdanov A. Environment-sensitive and enzyme-sensitive MR contrast agents. Handb. Exp. Pharmacol. 2008, 37-57.
26. + exchange in gastric glands as measured with a cytoplasmic-trapped, fluorescent pH indicator. Proc. Natl. Acad. Sci. U. S. A. 1984, 81:7436-7440.
27. Chacko V.P., Weiss R.G. Intracellular pH determination by 13C-NMR spectroscopy. Am. J. Physiol. 1993, 264:C755-C760.
28. Kneen M., Farinas J., Li Y., Verkman A.S. Green fluorescent protein as a noninvasive intracellular pH indicator. Biophys. J. 1998, 74:1591-1599.
29. Lowe M.P., Parker D., Reany O., Aime S., Botta M., Castellano G., Gianolio E., Pagliarin R. pH-dependent modulation of relaxivity and luminescence in macrocyclic gadolinium and europium complexes based on reversible intramolecular sulfonamide ligation. J. Am. Chem. Soc. 2001, 123:7601-7609.
30. Woods M., Kiefer G.E., Bott S., Castillo-Muzquiz A., Eshelbrenner C., Michaudet L., McMillan K., Mudigunda S.D., Ogrin D., Tircso G., Zhang S., Zhao P., Sherry A.D. Synthesis, relaxometric and photophysical properties of a new pH-responsive MRI contrast agent: the effect of other ligating groups on dissociation of a p-nitrophenolic pendant arm. J. Am. Chem. Soc. 2004, 126:9248-9256.
31. Barrett J.A., Coleman R.E., Goldsmith S.J., Vallabhajosula S., Petry N.A., Cho S., Armor T., Stubbs J.B., Maresca K.P., Stabin M.G., Joyal J.L., Eckelman W.C., Babich J.W. First-in-man evaluation of two high-affinity PSMA-avid small molecules for imaging prostate cancer. J. Nucl. Med. 2013.
32. Kaushal S., McElroy M.K., Luiken G.A., Talamini M.A., Moossa A.R., Hoffman R.M., Bouvet M. Fluorophore-conjugated anti-CEA antibody for the intraoperative imaging of pancreatic and colorectal cancer. J. Gastrointest. Surg. 2008, 12:1938-1950.
33. Tran Cao H.S., Kaushal S., Metildi C.A., Menen R.S., Lee C., Snyder C.S., Messer K., Pu M., Luiken G.A., Talamini M.A., Hoffman R.M., Bouvet M. Tumor-specific fluorescence antibody imaging enables accurate staging laparoscopy in an orthotopic model of pancreatic cancer. Hepato-Gastroenterology 2012, 59:1994-1999.
34. Zhou J., Hu L., Yu Z., Zheng J., Yang D., Bouvet M., Hoffman R.M. Marker expression in circulating cancer cells of pancreatic cancer patients. J. Surg. Res. 2011, 171:631-636.
35. Wu A.M., Yazaki P.J. Designer genes: recombinant antibody fragments for biological imaging. Q. J. Nucl. Med. 2000, 44:268-283.
36. Nguyen Q.T., Tsien R.Y. Fluorescence-guided surgery with live molecular navigation - a new cutting edge. Nature Reviews Cancer 2013.
37. Kohl G. The evolution and state-of-the-art principles of multislice computed tomography. Proc. Am. Thorac. Soc. 2005, 2:470-476. (499-500).
38. Shilo M., Reuveni T., Motiei M., Popovtzer R. Nanoparticles as computed tomography contrast agents: current status and future perspectives. Nanomedicine (Lond) 2012, 7:257-269.
39. Rabin O., Manuel Perez J., Grimm J., Wojtkiewicz G., Weissleder R. An X-ray computed tomography imaging agent based on long-circulating bismuth sulphide nanoparticles. Nat. Mater. 2006, 5:118-122.
40. Hyafil F., Cornily J.C., Feig J.E., Gordon R., Vucic E., Amirbekian V., Fisher E.A., Fuster V., Feldman L.J., Fayad Z.A. Noninvasive detection of macrophages using a nanoparticulate contrast agent for computed tomography. Nat. Med. 2007, 13:636-641.
41. Kapoor V., McCook B.M., Torok F.S. An introduction to PET-CT imaging. Radiographics: A Review Publication of the Radiological Society of North America, Inc. 2004, 24:523-543.
42. Bos R., van Der Hoeven J.J., van Der Wall E., van Der Groep P., van Diest P.J., Comans E.F., Joshi U., Semenza G.L., Hoekstra O.S., Lammertsma A.A., Molthoff C.F. Biologic correlates of (18)fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography. J. Clin. Oncol. 2002, 20:379-387.
43. Macheda M.L., Rogers S., Best J.D. Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer. J. Cell. Physiol. 2005, 202:654-662.
44. Juweid M.E. Utility of positron emission tomography (PET) scanning in managing patients with Hodgkin lymphoma. Hematology Am. Soc. Hematol. Educ. Program 2006, 259-265:251-510.
45. Conti P.S., Lilien D.L., Hawley K., Keppler J., Grafton S.T., Bading J.R. PET and [18F]-FDG in oncology: a clinical update. Nucl. Med. Biol. 1996, 23:717-735.
46. Buck A.K., Herrmann K., Stargardt T., Dechow T., Krause B.J., Schreyogg J. Economic evaluation of PET and PET/CT in oncology: evidence and methodologic approaches. J. Nucl. Med. 2010, 51:401-412.
47. Hricak H. Oncologic imaging: a guiding hand of personalized cancer care. Radiology 2011, 259:633-640.
48. Fletcher J.W., Kymes S.M., Gould M., Alazraki N., Coleman R.E., Lowe V.J., Marn C., Segall G., Thet L.A., Lee K. A comparison of the diagnostic accuracy of 18F-FDG PET and CT in the characterization of solitary pulmonary nodules. J. Nucl. Med. 2008, 49:179-185.
49. Gessner R., Dayton P.A. Advances in molecular imaging with ultrasound. Mol. Imaging 2010, 9:117-127.
50. Deshpande N., Needles A., Willmann J.K. Molecular ultrasound imaging: current status and future directions. Clin. Radiol. 2010, 65:567-581.
51. Lanza G.M., Wickline S.A. Targeted ultrasonic contrast agents for molecular imaging and therapy. Curr. Probl. Cardiol. 2003, 28:625-653.
52. Tardy I., Pochon S., Theraulaz M., Emmel P., Passantino L., Tranquart F., Schneider M. Ultrasound molecular imaging of VEGFR2 in a rat prostate tumor model using BR55. Invest. Radiol. 2010, 45:573-578.
53. Fischer T., Thomas A., Tardy I., Schneider M., Hunigen H., Custodis P., Beyersdorff D., Plendl J., Schnorr J., Diekmann F., Gemeinhardt O. Vascular endothelial growth factor receptor 2-specific microbubbles for molecular ultrasound detection of prostate cancer in a rat model. Invest. Radiol. 2010, 45:675-684.
54. Willmann J.K., Kimura R.H., Deshpande N., Lutz A.M., Cochran J.R., Gambhir S.S. Targeted contrast-enhanced ultrasound imaging of tumor angiogenesis with contrast microbubbles conjugated to integrin-binding knottin peptides. J. Nucl. Med. 2010, 51:433-440.
55. Pysz M.A., Foygel K., Rosenberg J., Gambhir S.S., Schneider M., Willmann J.K. Antiangiogenic cancer therapy: monitoring with molecular US and a clinically translatable contrast agent (BR55). Radiology 2010, 256:519-527.
56. Matsumura Y., Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 1986, 46:6387-6392.
57. Maeda H. The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Adv. Enzyme Regul. 2001, 41:189-207.
58. Rapoport N., Gao Z., Kennedy A. Multifunctional nanoparticles for combining ultrasonic tumor imaging and targeted chemotherapy. J. Natl. Cancer Inst. 2007, 99:1095-1106.
59. Gao Z.G., Fain H.D., Rapoport N. Controlled and targeted tumor chemotherapy by micellar-encapsulated drug and ultrasound. J. Control. Release. 2005, 102:203-222.
60. Fang J., Nakamura H., Maeda H. The EPR effect: unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv. Drug Deliv. Rev. 2011, 63:136-151.
61. Willmann J.K., van Bruggen N., Dinkelborg L.M., Gambhir S.S. Molecular imaging in drug development. Nat. Rev. Drug Discov. 2008, 7:591-607.
62. Massoud T.F., Gambhir S.S. Molecular imaging in living subjects: seeing fundamental biological processes in a new light. Genes Dev. 2003, 17:545-580.
63. Jacobs R.E., Cherry S.R. Complementary emerging techniques: high-resolution PET and MRI. Curr. Opin. Neurobiol. 2001, 11:621-629.
64. Kim C.K., Park B.K., Lee H.M., Kwon G.Y. Value of diffusion-weighted imaging for the prediction of prostate cancer location at 3T using a phased-array coil: preliminary results. Invest. Radiol. 2007, 42:842-847.
65. Gibbs P., Pickles M.D., Turnbull L.W. Diffusion imaging of the prostate at 3.0Tesla. Invest. Radiol. 2006, 41:185-188.
66. Pickles M.D., Gibbs P., Sreenivas M., Turnbull L.W. Diffusion-weighted imaging of normal and malignant prostate tissue at 3.0T. J. Magn. Reson. Imaging 2006, 23:130-134.
67. Ohno Y., Koyama H., Onishi Y., Takenaka D., Nogami M., Yoshikawa T., Matsumoto S., Kotani Y., Sugimura K. Non-small cell lung cancer: whole-body MR examination for M-stage assessment-utility for whole-body diffusion-weighted imaging compared with integrated FDG PET/CT. Radiology 2008, 248:643-654.
68. Vargas H.A., Akin O., Franiel T., Mazaheri Y., Zheng J., Moskowitz C., Udo K., Eastham J., Hricak H. Diffusion-weighted endorectal MR imaging at 3T for prostate cancer: tumor detection and assessment of aggressiveness. Radiology 2011, 259:775-784.
69. Islam T., Josephson L. Current state and future applications of active targeting in malignancies using superparamagnetic iron oxide nanoparticles. Cancer Biomark 2009, 5:99-107.
70. Thorek D.L., Chen A.K., Czupryna J., Tsourkas A. Superparamagnetic iron oxide nanoparticle probes for molecular imaging. Ann. Biomed. Eng. 2006, 34:23-38.
71. Harisinghani M.G., Barentsz J., Hahn P.F., Deserno W.M., Tabatabaei S., van de Kaa C.H., de la Rosette J., Weissleder R. Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N. Engl. J. Med. 2003, 348:2491-2499.
72. Wunderbaldinger P., Josephson L., Bremer C., Moore A., Weissleder R. Detection of lymph node metastases by contrast-enhanced MRI in an experimental model. Magn. Reson. Med. 2002, 47:292-297.
73. Boles K.S., Schmieder A.H., Koch A.W., Carano R.A., Wu Y., Caruthers S.D., Tong R.K., Stawicki S., Hu G., Scott M.J., Zhang H., Reynolds B.A., Wickline S.A., Lanza G.M. MR angiogenesis imaging with Robo4- vs. alphaVbeta3-targeted nanoparticles in a B16/F10 mouse melanoma model. FASEB J. 2010, 24:4262-4270.
74. Kresse M., Wagner S., Pfefferer D., Lawaczeck R., Elste V., Semmler W. Targeting of ultrasmall superparamagnetic iron oxide (USPIO) particles to tumor cells in vivo by using transferrin receptor pathways. Magn. Reson. Med. 1998, 40:236-242.
75. Choi H., Choi S.R., Zhou R., Kung H.F., Chen I.W. Iron oxide nanoparticles as magnetic resonance contrast agent for tumor imaging via folate receptor-targeted delivery. Acad. Radiol. 2004, 11:996-1004.
76. Konda S.D., Aref M., Brechbiel M., Wiener E.C. Development of a tumor-targeting MR contrast agent using the high-affinity folate receptor: work in progress. Invest. Radiol. 2000, 35:50-57.
77. Antony A.C. Folate receptors. Annu. Rev. Nutr. 1996, 16:501-521.
78. Lu Y., Low P.S. Folate-mediated delivery of macromolecular anticancer therapeutic agents. Adv. Drug Deliv. Rev. 2002, 54:675-693.
79. Cunningham C.H., Arai T., Yang P.C., McConnell M.V., Pauly J.M., Conolly S.M. Positive contrast magnetic resonance imaging of cells labeled with magnetic nanoparticles. Magn. Reson. Med. 2005, 53:999-1005.
80. Wu S., Zhang L., Zhong J., Zhang Z. Dual contrast magnetic resonance imaging tracking of iron-labeled cells in vivo. Cytotherapy 2010, 12:859-869.
81. Sosnovik D.E., Nahrendorf M., Weissleder R. Molecular magnetic resonance imaging in cardiovascular medicine. Circulation 2007, 115:2076-2086.
82. Morawski A.M., Winter P.M., Crowder K.C., Caruthers S.D., Fuhrhop R.W., Scott M.J., Robertson J.D., Abendschein D.R., Lanza G.M., Wickline S.A. Targeted nanoparticles for quantitative imaging of sparse molecular epitopes with MRI. Magn. Reson. Med. 2004, 51:480-486.
83. Aime S., Cabella C., Colombatto S., Geninatti Crich S., Gianolio E., Maggioni F. Insights into the use of paramagnetic Gd(III) complexes in MR-molecular imaging investigations. J. Magn. Reson. Imaging 2002, 16:394-406.
84. Rodriguez E., Nilges M., Weissleder R., Chen J.W. Activatable magnetic resonance imaging agents for myeloperoxidase sensing: mechanism of activation, stability, and toxicity. J. Am. Chem. Soc. 2010, 132:168-177.
85. Xu X., Wang Y., Chen Z., Sternlicht M.D., Hidalgo M., Steffensen B. Matrix metalloproteinase-2 contributes to cancer cell migration on collagen. Cancer Res. 2005, 65:130-136.
86. Lepage M., Dow W.C., Melchior M., You Y., Fingleton B., Quarles C.C., Pepin C., Gore J.C., Matrisian L.M., McIntyre J.O. Noninvasive detection of matrix metalloproteinase activity in vivo using a novel magnetic resonance imaging contrast agent with a solubility switch. Mol. Imaging 2007, 6:393-403.
87. Lebel R., Jastrzebska B., Therriault H., Cournoyer M.M., McIntyre J.O., Escher E., Neugebauer W., Paquette B., Lepage M. Novel solubility-switchable MRI agent allows the noninvasive detection of matrix metalloproteinase-2 activity in vivo in a mouse model. Magn. Reson. Med. 2008, 60:1056-1065.
88. Gringeri C.V., Menchise V., Rizzitelli S., Cittadino E., Catanzaro V., Dati G., Chaabane L., Digilio G., Aime S. Novel Gd(III)-based probes for MR molecular imaging of matrix metalloproteinases. Contrast Media Mol. Imaging 2012, 7:175-184.
89. Schellenberger E., Rudloff F., Warmuth C., Taupitz M., Hamm B., Schnorr J. Protease-specific nanosensors for magnetic resonance imaging. Bioconjug. Chem. 2008, 19:2440-2445.
90. Schwarze S.R., Dowdy S.F. In vivo protein transduction: intracellular delivery of biologically active proteins, compounds and DNA. Trends Pharmacol. Sci. 2000, 21:45-48.
91. Torchilin V.P. Tat peptide-mediated intracellular delivery of pharmaceutical nanocarriers. Adv. Drug Deliv. Rev. 2008, 60:548-558.
92. Jiang T., Olson E.S., Nguyen Q.T., Roy M., Jennings P.A., Tsien R.Y. Tumor imaging by means of proteolytic activation of cell-penetrating peptides. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:17867-17872.
93. Aguilera T.A., Olson E.S., Timmers M.M., Jiang T., Tsien R.Y. Systemic in vivo distribution of activatable cell penetrating peptides is superior to that of cell penetrating peptides. Integr. Biol. (Camb) 2009, 1:371-381.
94. Olson E.S., Aguilera T.A., Jiang T., Ellies L.G., Nguyen Q.T., Wong E.H., Gross L.A., Tsien R.Y. In vivo characterization of activatable cell penetrating peptides for targeting protease activity in cancer. Integr. Biol. (Camb) 2009, 1:382-393.
95. Olson E.S., Jiang T., Aguilera T.A., Nguyen Q.T., Ellies L.G., Scadeng M., Tsien R.Y. Activatable cell penetrating peptides linked to nanoparticles as dual probes for in vivo fluorescence and MR imaging of proteases. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:4311-4316.
96. Nguyen Q.T., Olson E.S., Aguilera T.A., Jiang T., Scadeng M., Ellies L.G., Tsien R.Y. Surgery with molecular fluorescence imaging using activatable cell-penetrating peptides decreases residual cancer and improves survival. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:4317-4322.
97. Stummer W., Pichlmeier U., Meinel T., Wiestler O.D., Zanella F., Reulen H.J., Group A.L.-G.S. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol. 2006, 7:392-401.
98. van Dam G.M., Themelis G., Crane L.M., Harlaar N.J., Pleijhuis R.G., Kelder W., Sarantopoulos A., de Jong J.S., Arts H.J., van der Zee A.G., Bart J., Low P.S., Ntziachristos V. Intraoperative tumor-specific fluorescence imaging in ovarian cancer by folate receptor-alpha targeting: first in-human results. Nat. Med. 2011, 17:1315-1319.
99. Wieder J.A., Soloway M.S. Incidence, etiology, location, prevention and treatment of positive surgical margins after radical prostatectomy for prostate cancer. J. Urol. 1998, 160:299-315.
100. Singletary S.E. Surgical margins in patients with early-stage breast cancer treated with breast conservation therapy. Am. J. Surg. 2002, 184:383-393.
101. Meric F., Mirza N.Q., Vlastos G., Buchholz T.A., Kuerer H.M., Babiera G.V., Singletary S.E., Ross M.I., Ames F.C., Feig B.W., Krishnamurthy S., Perkins G.H., McNeese M.D., Strom E.A., Valero V., Hunt K.K. Positive surgical margins and ipsilateral breast tumor recurrence predict disease-specific survival after breast-conserving therapy. Cancer 2003, 97:926-933.
102. Haque R., Contreras R., McNicoll M.P., Eckberg E.C., Petitti D.B. Surgical margins and survival after head and neck cancer surgery. BMC Ear Nose Throat Disord. 2006, 6:2.
103. Dotan Z.A., Kavanagh K., Yossepowitch O., Kaag M., Olgac S., Donat M., Herr H.W. Positive surgical margins in soft tissue following radical cystectomy for bladder cancer and cancer specific survival. J. Urol. 2007, 178:2308-2312. (discussion 2313).
104. Nagtegaal I.D., Quirke P. What is the role for the circumferential margin in the modern treatment of rectal cancer?. J. Clin. Oncol. 2008, 26:303-312.
105. Stummer W., Reulen H.J., Meinel T., Pichlmeier U., Schumacher W., Tonn J.C., Rohde V., Oppel F., Turowski B., Woiciechowsky C., Franz K., Pietsch T. Extent of resection and survival in glioblastoma multiforme: identification of and adjustment for bias. Neurosurgery 2008, 62:564-576. (discussion 564-576).
106. Pavlova I., Hume K.R., Yazinski S.A., Flanders J., Southard T.L., Weiss R.S., Webb W.W. Multiphoton microscopy and microspectroscopy for diagnostics of inflammatory and neoplastic lung. J. Biomed. Opt. 2012, 17:036014.
107. Pierce M.C., Schwarz R.A., Bhattar V.S., Mondrik S., Williams M.D., Lee J.J., Richards-Kortum R., Gillenwater A.M. Accuracy of in vivo multimodal optical imaging for detection of oral neoplasia. Cancer Prev. Res. (Phila) 2012, 5:801-809.
108. Vila P.M., Park C.W., Pierce M.C., Goldstein G.H., Levy L., Gurudutt V.V., Polydorides A.D., Godbold J.H., Teng M.S., Genden E.M., Miles B.A., Anandasabapathy S., Gillenwater A.M., Richards-Kortum R., Sikora A.G. Discrimination of benign and neoplastic mucosa with a high-resolution microendoscope (HRME) in head and neck cancer. Ann. Surg. Oncol. 2012, 19:3534-3539.
109. Delank W., Khanavkar B., Nakhosteen J.A., Stoll W. A pilot study of autofluorescent endoscopy for the in vivo detection of laryngeal cancer. Laryngoscope 2000, 110:368-373.
110. Malzahn K., Dreyer T., Glanz H., Arens C. Autofluorescence endoscopy in the diagnosis of early laryngeal cancer and its precursor lesions. Laryngoscope 2002, 112:488-493.
111. Haglund M.M., Berger M.S., Hochman D.W. Enhanced optical imaging of human gliomas and tumor margins. Neurosurgery 1996, 38:308-317.
112. Colen R.R., Kekhia H., Jolesz F.A. Multimodality intraoperative MRI for brain tumor surgery. Expert. Rev. Neurother. 2010, 10:1545-1558.
113. Troyan S.L., Kianzad V., Gibbs-Strauss S.L., Gioux S., Matsui A., Oketokoun R., Ngo L., Khamene A., Azar F., Frangioni J.V. The FLARE intraoperative near-infrared fluorescence imaging system: a first-in-human clinical trial in breast cancer sentinel lymph node mapping. Ann. Surg. Oncol. 2009, 16:2943-2952.
114. Schaafsma B.E., Mieog J.S., Hutteman M., van der Vorst J.R., Kuppen P.J., Lowik C.W., Frangioni J.V., van de Velde C.J., Vahrmeijer A.L. The clinical use of indocyanine green as a near-infrared fluorescent contrast agent for image-guided oncologic surgery. J. Surg. Oncol. 2011, 104:323-332.
115. Regula J., MacRobert A.J., Gorchein A., Buonaccorsi G.A., Thorpe S.M., Spencer G.M., Hatfield A.R., Bown S.G. Photosensitisation and photodynamic therapy of oesophageal, duodenal, and colorectal tumours using 5 aminolaevulinic acid induced protoporphyrin IX-a pilot study. Gut 1995, 36:67-75.
116. Stummer W., Novotny A., Stepp H., Goetz C., Bise K., Reulen H.J. Fluorescence-guided resection of glioblastoma multiforme by using 5-aminolevulinic acid-induced porphyrins: a prospective study in 52 consecutive patients. J. Neurosurg. 2000, 93:1003-1013.
117. Floeth F.W., Sabel M., Ewelt C., Stummer W., Felsberg J., Reifenberger G., Steiger H.J., Stoffels G., Coenen H.H., Langen K.J. Comparison of (18)F-FET PET and 5-ALA fluorescence in cerebral gliomas. Eur. J. Nucl. Med. Mol. Imaging 2011, 38:731-741.
118. Nakajima T., Mitsunaga M., Bander N.H., Heston W.D., Choyke P.L., Kobayashi H. Targeted, activatable, in vivo fluorescence imaging of prostate-specific membrane antigen (PSMA) positive tumors using the quenched humanized J591 antibody-indocyanine green (ICG) conjugate. Bioconjug. Chem. 2011, 22:1700-1705.
119. Kelderhouse L.E., Chelvam V., Wayua C., Mahalingam S., Poh S., Kularatne S.A., Low P.S. Development of tumor-targeted near infrared probes for fluorescence guided surgery. Bioconjug. Chem. 2013, 24:1075-1080.
120. Klohs J., Wunder A., Licha K. Near-infrared fluorescent probes for imaging vascular pathophysiology. Basic Res. Cardiol. 2008, 103:144-151.
121. Taggart D.P., Choudhary B., Anastasiadis K., Abu-Omar Y., Balacumaraswami L., Pigott D.W. Preliminary experience with a novel intraoperative fluorescence imaging technique to evaluate the patency of bypass grafts in total arterial revascularization. Ann. Thorac. Surg. 2003, 75:870-873.
122. Raabe A., Beck J., Gerlach R., Zimmermann M., Seifert V. Near-infrared indocyanine green video angiography: a new method for intraoperative assessment of vascular flow. Neurosurgery 2003, 52:132-139. discussion 139.
123. Tanaka E., Ohnishi S., Laurence R.G., Choi H.S., Humblet V., Frangioni J.V. Real-time intraoperative ureteral guidance using invisible near-infrared fluorescence. J. Urol. 2007, 178:2197-2202.
124. Matsui A., Tanaka E., Choi H.S., Kianzad V., Gioux S., Lomnes S.J., Frangioni J.V. Real-time, near-infrared, fluorescence-guided identification of the ureters using methylene blue. Surgery 2010, 148:78-86.
125. Bron L.P., O'Brien C.J. Facial nerve function after parotidectomy. Arch. Otolaryngol. Head Neck Surg. 1997, 123:1091-1096.
126. Nouraei S.A., Ismail Y., Ferguson M.S., McLean N.R., Milner R.H., Thomson P.J., Welch A.R. Analysis of complications following surgical treatment of benign parotid disease. ANZ J. Surg. 2008, 78:134-138.
127. Kubler H.R., Tseng T.Y., Sun L., Vieweg J., Harris M.J., Dahm P. Impact of nerve sparing technique on patient self-assessed outcomes after radical perineal prostatectomy. J. Urol. 2007, 178:488-492. (discussion 492).
128. Sturniolo G., D'Alia C., Tonante A., Gagliano E., Taranto F., Lo Schiavo M.G. The recurrent laryngeal nerve related to thyroid surgery. Am. J. Surg. 1999, 177:485-488.
129. Miller M.C., Spiegel J.R. Identification and monitoring of the recurrent laryngeal nerve during thyroidectomy. Surg. Oncol. Clin. N. Am. 2008, 17:121-144. (viii-ix).
130. Gantz B.J. Intraoperative facial nerve monitoring. Am J Otol 1985, 58-61. (Suppl.).
131. Kobbert C., Apps R., Bechmann I., Lanciego J.L., Mey J., Thanos S. Current concepts in neuroanatomical tracing. Prog. Neurobiol. 2000, 62:327-351.
132. Marangos N., Illing R.B., Kruger J., Laszig R. In vivo visualization of the cochlear nerve and nuclei with fluorescent axonal tracers. Hear. Res. 2001, 162:48-52.
133. Whitney M.A., Crisp J.L., Nguyen L.T., Friedman B., Gross L.A., Steinbach P., Tsien R.Y., Nguyen Q.T. Fluorescent peptides highlight peripheral nerves during surgery in mice. Nat. Biotechnol. 2011, 29:352-356.
134. Wu A.P., Whitney M.A., Crisp J.L., Friedman B., Tsien R.Y., Nguyen Q.T. Improved facial nerve identification with novel fluorescently labeled probe. Laryngoscope 2011, 121:805-810.
135. Orosco R.K., Tsien R.Y., Nguyen Q.T. Fluorescence imaging in surgery. IEEE Rev. Biomed. Eng. 2013, 6:178-187.
136. Nunn A.D. The cost of developing imaging agents for routine clinical use. Investig. Radiol. 2006, 41:206-212.
137. Hoffman J.M., Gambhir S.S., Kelloff G.J. Regulatory and reimbursement challenges for molecular imaging. Radiology 2007, 245:645-660.
138. Taruttis A., Ntziachristos V. Translational optical imaging. AJR. Am. J. Roentgenol. 2012, 199:263-271.
139. Klibanov A.L., Rasche P.T., Hughes M.S., Wojdyla J.K., Galen K.P., Wible J.H., Brandenburger G.H. Detection of individual microbubbles of ultrasound contrast agents: imaging of free-floating and targeted bubbles. Investig. Radiol. 2004, 39:187-195.
140. Hancu I., Dixon W.T., Woods M., Vinogradov E., Sherry A.D., Lenkinski R.E. CEST and PARACEST MR contrast agents. Acta Radiol. 2010, 51:910-923.
141. Kelloff G.J., Krohn K.A., Larson S.M., Weissleder R., Mankoff D.A., Hoffman J.M., Link J.M., Guyton K.Z., Eckelman W.C., Scher H.I., O'Shaughnessy J., Cheson B.D., Sigman C.C., Tatum J.L., Mills G.Q., Sullivan D.C., Woodcock J. The progress and promise of molecular imaging probes in oncologic drug development. Clin. Cancer Res. 2005, 11:7967-7985.